For pharma, the mention is only the beginning.
VizLoop connects AI visibility with the source that matters to your review: versioned Prescribing Information. Inspect the answer, its citations, and the label evidence together.
From a visibility signal to a reviewable record.
A mention count or citation alone does not establish whether an answer carries a boxed warning or contraindication. These are the questions our pharma workflow is built to make inspectable.
| Review dimension | Visibility signal | VizLoop’s pharma evidence record |
|---|---|---|
| Question | Where is the product mentioned? | Which question produced this answer, what does it cite, and how does it compare with the label? |
| Reference | The captured answer and its sources. | The captured answer plus the archived, versioned Prescribing Information. |
| Evidence | Mentions and cited pages. | Label sections, answer spans, model and method identifiers, and capture dates. |
| Review | Interpret the visibility signal. | Inspect carried, partial, or absent safety elements; review unverified spans and missing evidence explicitly. |
| Teams | Commercial and brand. | Commercial, medical affairs, regulatory and legal, and Pharmacovigilance share the same record. |
This describes our workflow, not a claim that every other tool lacks these capabilities. Coverage depends on the configured surfaces and available evidence.
Evidence for four functions.
Commercial can inspect product answers and citations. Medical affairs can review the questions and verbatim responses. Regulatory and legal can trace the source version and method. Pharmacovigilance can inspect the safety element behind a finding.
Label substantiation is a comparison for human review. Model judgments can disagree or contain errors. A finding is not a compliance determination, and the monitoring record does not establish patient exposure or clinical harm.